Divis Laboratories Gains 6.18%: 6 Key Factors Driving the Week’s Momentum

Monday, 13 July 2026: Steady Start with Modest Gains

Divis Laboratories began the week on a positive note, closing at Rs.6,933.15, up 1.43% from the previous Friday’s close of Rs.6,835.70. This gain was achieved on relatively low volume of 5,232 shares, while the Sensex remained nearly flat, rising a marginal 0.01% to 36,508.75. The stock’s outperformance set the tone for the week, signalling early investor interest amid a stable market environment.

Tuesday, 14 July 2026: Breakout to New 52-Week Highs Amid Active Options Trading

On 14 July, Divis Laboratories surged 3.64% to close at Rs.7,185.20, hitting a new 52-week high of Rs.6,976.80 earlier in the session and an intraday peak of Rs.7,150. This strong performance was notable as the Sensex declined 0.67% to 36,265.57, highlighting the stock’s relative strength. The day was marked by exceptional derivatives activity, with the stock becoming the most active in both call and put options at the ₹7,000 strike for the 28 July expiry.

Call options saw 22,005 contracts traded, generating a turnover of ₹3,165.42 lakhs, while put options recorded 5,331 contracts with a turnover of ₹66.0 crores. Open interest surged by 13.3%, reflecting fresh bullish positioning despite some hedging indicated by put volumes. The stock’s technical indicators remained bullish, trading above all key moving averages and supported by a Mojo Grade of Hold with a score of 64.0 at the time.

Wednesday, 15 July 2026: All-Time High and Mojo Upgrade to Buy

Divis Laboratories continued its upward trajectory, hitting a new 52-week and all-time high of Rs.7,324.15 on 15 July, closing the day at Rs.7,284.60, up 1.38%. This gain outpaced the Pharmaceuticals & Biotechnology sector by 1.61% and the Sensex, which rose 0.31% to 36,378.34. The stock recorded its fifth consecutive day of gains, accumulating an 8.34% return over this period.

Significantly, MarketsMOJO upgraded Divis Laboratories’ mojo rating from Hold to Buy on 14 July, reflecting improved technical momentum and strong financial performance. The mojo score rose to 71.0, supported by bullish weekly MACD, Bollinger Bands, and Dow Theory signals. Delivery volumes surged by 112.65% over the five-day average, indicating genuine investor participation beyond speculative trading.

Call option activity remained robust, with the 7,300 and 7,500 strike prices attracting high volumes and open interest, signalling bullish market expectations ahead of the 28 July expiry.

Thursday, 16 July 2026: Sixth Consecutive Gain and New 52-Week High

On 16 July, Divis Laboratories set another 52-week high at Rs.7,345, closing at Rs.7,319.75, up 0.48%. This marked six consecutive days of gains and an 8.71% return over the period. The stock outperformed its sector by 0.86%, while the Sensex was marginally down 0.13% at 36,331.82. The trading range was narrow, indicating steady buying interest with controlled volatility.

Technical indicators remained predominantly bullish, with the stock trading above all key moving averages and supported by positive weekly MACD and Bollinger Bands. The company’s strong quarterly financials, including record net sales of Rs.2,831 crore and PBDIT of Rs.934 crore, underpinned investor confidence. Institutional holdings remained high at 39.51%, reflecting sustained market trust.

Friday, 17 July 2026: Slight Pullback but Weekly Gains Intact

Divis Laboratories closed the week at Rs.7,258.05, down 0.84% on the day, with a volume of 42,647 shares. Despite the minor pullback, the stock posted a strong weekly gain of 6.18%, significantly outperforming the Sensex which was essentially flat. The slight profit-taking on Friday followed six days of sustained gains and multiple new highs.

Technical momentum remains positive, supported by a recent upgrade to a Buy rating and a mojo score of 71.0. The stock’s premium valuation, with a price-to-book ratio of 11.5 and PEG ratio of 3.7, reflects market expectations of continued operational strength and quality earnings growth. Investors should note the mixed signals from monthly technical indicators, which counsel monitoring for potential volatility ahead.

Key Takeaways

Positive Signals: Divis Laboratories demonstrated strong price momentum, hitting multiple 52-week and all-time highs, supported by robust quarterly financials and a net-debt-free balance sheet. The upgrade to a Buy rating and a mojo score of 71.0 reflect improved technical and fundamental outlooks. Active call option activity and rising open interest indicate bullish market positioning. Institutional holdings remain substantial, underscoring confidence from sophisticated investors.

Cautionary Notes: Despite the strong rally, the stock trades at a premium valuation with a price-to-book ratio above 11 and a PEG ratio of 3.7, suggesting expectations are high. Monthly technical indicators such as MACD and KST show mild bearishness, and delivery volumes have fluctuated, indicating some caution among longer-term investors. The surge in put option activity alongside calls signals hedging and mixed sentiment ahead of the 28 July expiry.

Conclusion

Divis Laboratories Ltd’s performance in the week ending 17 July 2026 was marked by sustained gains, multiple new highs, and a significant mojo rating upgrade, reflecting a strong technical and fundamental position. The stock’s outperformance relative to the Sensex and sector peers highlights its leadership within the Pharmaceuticals & Biotechnology industry. While the premium valuation and mixed monthly technical signals advise prudence, the overall momentum and active derivatives market participation suggest that Divis Laboratories remains a key focus for investors and traders navigating the sector’s evolving landscape.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →